Login

Financial Snapshot

Revenue
TTM
$0.00
Gross Margin
Last 4 Quarters
N/A
Net Income
TTM
-$28.19M
Current Assets
2025 Q4
Current Liabilities
2025 Q4
Current Ratio
2025 Q4
30.92%
Total Assets
2025 Q4
Total Liabilities
2025 Q4
Book Value
2025 Q4
-$1.560M
Cash
2025 Q4
P/E
Last 4 Quarters
N/A
Free Cash Flow
TTM
-$12.06M

Stock Price

Loading...
Market Cap: $27.587 Million

About Neurosense Therapeutics Ltd

Neurosense Therapeutics Ltd. is a clinical-stage biotechnology company, which engages n the discovery and development of targeted therapeutics for neurodegenerative diseases. The firm is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The firm's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease

Industry: Pharmaceutical Preparations Peers: Pluri Inc Chemomab Therapeutics Ltd BiomX Inc Galmed Pharmaceuticals Ltd Notable Labs, Ltd.

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support